Intellect Neurosciences, Inc. Issues Letter to Shareholders
3/29/2013 10:19:53 AM
More...
|
Intellect Neurosciences, Inc. CEO Daniel Chain Provides Conference Highlights of Alzheimer's Drug Development Summit in Neurotech Insights Magazine
1/2/2013 9:24:04 AM
More...
|
Intellect Neurosciences, Inc. Issues Letter to Shareholders
10/16/2012 9:36:34 AM
More...
|
Intellect Neurosciences, Inc. Files Lawsuit Against Pharmaceutical Licensee for Non Payment of $2 Million Milestone
10/15/2012 9:36:41 AM
More...
|
Intellect Neurosciences, Inc. and iNovacia Enter Research Service Agreement to Evaluate Lead Compounds for CONJUMAB-A Program
10/3/2012 9:36:19 AM
More...
|
Intellect Neurosciences, Inc. and Medical Research Council Technology Announce Humanization of Next-Generation Monoclonal Antibody to Amyloid Beta With Reduced Potential for Inflammation in the Brain of Alzheimer's Patients
9/19/2012 9:19:58 AM
More...
|
Intellect Neurosciences, Inc. Issues Letter to Shareholders
8/8/2012 10:02:40 AM
More...
|
Intellect Neurosciences, Inc. Adds Two New Patent Allowances to Its Global Patent Portfolio
8/1/2012 9:05:06 AM
More...
|
Intellect Neurosciences, Inc. to Present at Antibody Summit in San Francisco
7/23/2012 9:39:04 AM
More...
|
Intellect Neurosciences, Inc. in Dispute With Pharmaceutical Licensee Over $2 Million Milestone Payment
7/12/2012 9:52:32 AM
More...
|
|